Science & Research

The Multivariate Effect of Ketamine on PTSD: Systematic Review and Meta-Analysis

Rui Du, Ruili Han, Kun Niu, Jiaqiao Xu, Zihou Zhao, Guofang Lu and Yulong Shang Published 9 March 2022 | https://doi.org/10.3389/fpsyt.2022.813103 Abstract Background: Post-traumatic stress disorder (PTSD) is a serious stress-related disorder caused by traumatic experiences. However, identifying a key therapy that can be used for PTSD treatment remains difficult. Ketamine, a well-known dissociative anesthetic, […]

The Multivariate Effect of Ketamine on PTSD: Systematic Review and Meta-Analysis Read More »

Ketamine for Adolescent Suicidality

In the meantime, practitioners of this new kind of mental healthcare can use ketamine as their psychedelic agent; and some studies, such as the one Grant participated in, are even government funded. The Ketamine for Reduction of Alcoholic Relapse (Kare) study is a novel attempt to ease the huge burden on the NHS caused by alcohol-related illnesses.

Ketamine for Adolescent Suicidality Read More »

Dose-related effects of ketamine for antidepressant-resistant symptoms of posttraumatic stress disorder in veterans and active duty military: a double-blind, randomized, placebo-controlled multi-center clinical trial

Chadi G. Abdallah, John D. Roache, Ralitza Gueorguieva, Lynnette A. Averill, Stacey Young-McCaughan, Paulo R. Shiroma, Prerana Purohit, Antoinette Brundige, William Murff, Kyung-Heup Ahn, Mohamed A. Sherif, Eric J. Baltutis, Mohini Ranganathan, Deepak D’Souza, Brenda Martini, Steven M. Southwick, Ismene L. Petrakis, Rebecca R. Burson, Kevin B. Guthmiller, Argelio L. López-Roca, Karl A. Lautenschlager, John

Dose-related effects of ketamine for antidepressant-resistant symptoms of posttraumatic stress disorder in veterans and active duty military: a double-blind, randomized, placebo-controlled multi-center clinical trial Read More »

Systematic review and meta-analysis of randomized controlled trials of ketamine in the treatment of refractory anxiety spectrum disorders

Elizabeth Whittaker, Alisher R. Dadabayev, Sonalee A. Joshi, Paul Glue Published 15 December 2021| https://doi.org/10.1177/20451253211056743 Abstract Background: Anxiety disorders are common, associated with significant burden of disease, and have high levels of treatment resistance. Low-dose ketamine has been extensively studied in treatment-resistant depression, with fewer reports in treatment-resistant anxiety disorders. Aims: This systematic review and

Systematic review and meta-analysis of randomized controlled trials of ketamine in the treatment of refractory anxiety spectrum disorders Read More »

Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation

Roger S. McIntyre, M.D., Joshua D. Rosenblat, M.D., M.Sc., Charles B. Nemeroff, M.D., Ph.D., Gerard Sanacora, M.D., Ph.D., James W. Murrough, M.D., Ph.D., Michael Berk, Ph.D., M.B.B.Ch., Elisa Brietzke, M.D., Ph.D., Seetal Dodd, Ph.D., Philip Gorwood, M.D., Ph.D., Roger Ho, M.D., M.B.B.S., Dan V. Iosifescu, M.D., Carlos Lopez Jaramillo, M.D., Ph.D., Siegfried Kasper, M.D., Kevin

Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation Read More »

Ketamine Use for Cancer and Chronic Pain Management

Clayton Culp, Hee Kee Kim and Salahadin Abdi Published 2 February 2021 | https://doi.org/10.3389/fphar.2020.599721 Abstract Ketamine, an N-methyl-D-aspartate receptor antagonist, is widely known as a dissociative anesthetic and phencyclidine derivative. Due to an undesirable adverse event profile when used as an anesthetic it had widely fallen out of human use in favor of more modern

Ketamine Use for Cancer and Chronic Pain Management Read More »

The Effects of Ketamine on Cognition in Treatment-Resistant Depression: A Systematic Review and Priority Avenues for Future Research

Hartej Gill, Barjot Gill, Nelson B. Rodrigues, Orly Lipsitz, Joshua Daniel Rosenblat, Sabine El-Halabi, Flora Nasri, Rodrigo B. Mansur, Yena Lee, Roger S. McIntyre Published 23 November 2020 | https://doi.org/10.1016/j.neubiorev.2020.11.020 Abstract Replicated evidence has documented cognitive deficits in populations with treatment-resistant depression (TRD). Approximately 40 % of patients with MDD present with impairment of one

The Effects of Ketamine on Cognition in Treatment-Resistant Depression: A Systematic Review and Priority Avenues for Future Research Read More »

Scroll to Top